Cargando…

Process evaluation of the impact and acceptability of a polypill for prevention of cardiovascular disease

IMPORTANCE: The Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE) trial has shown improved adherence with the use of a polypill strategy when compared with usual medications for cardiovascular disease (CVD) prevention. To advance from efficacy to impact, we need a better understandi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wood, Frances, Salam, Abdul, Singh, Kavita, Day, Sophie, Jan, Stephen, Prabhakaran, Dorairaj, Rodgers, Anthony, Patel, Anushka, Thom, Simon, Ward, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4593141/
https://www.ncbi.nlm.nih.gov/pubmed/26423850
http://dx.doi.org/10.1136/bmjopen-2015-008018
_version_ 1782393279633948672
author Wood, Frances
Salam, Abdul
Singh, Kavita
Day, Sophie
Jan, Stephen
Prabhakaran, Dorairaj
Rodgers, Anthony
Patel, Anushka
Thom, Simon
Ward, Helen
author_facet Wood, Frances
Salam, Abdul
Singh, Kavita
Day, Sophie
Jan, Stephen
Prabhakaran, Dorairaj
Rodgers, Anthony
Patel, Anushka
Thom, Simon
Ward, Helen
author_sort Wood, Frances
collection PubMed
description IMPORTANCE: The Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE) trial has shown improved adherence with the use of a polypill strategy when compared with usual medications for cardiovascular disease (CVD) prevention. To advance from efficacy to impact, we need a better understanding of why and how such a strategy might be deployed in complex health systems. OBJECTIVE: To understand, from the perspective of UMPIRE trial participants and professionals, how and why a polypill strategy improves adherence compared with usual care, why improvement is greater in some subgroups, and to explore the acceptability of a polypill strategy among trial participants and healthcare professionals. DESIGN, SETTING AND PARTICIPANTS: A preplanned process evaluation, based on qualitative interviews, was conducted with a subsample of 102 trial participants and 41 healthcare professionals at the end of the UMPIRE trial in India and Europe. RESULTS: Most patients contrasted the simplicity of the polypill with usual medications that they found complex and, for many in India, expensive. Patients with low baseline adherence struggled most with complex medication lists, and those without established disease described less motivation to adhere when compared with people who had already been diagnosed with CVD; people in the latter group had already undertaken self-directed measures to adhere to CVD preventive medicines prior to entering the trial. Taking medication was one of many adaptations described by patients; these included dietary changes, stopping smoking and maintaining exercise. Most patients liked the polypill strategy, although some participants and health professionals were concerned that it would provide less tailored therapy for individual needs. CONCLUSIONS: Adherence to treatment lists with multiple medications is complex and influenced by several factors. Simplifying medication by using a once-daily polypill is one approach to CVD prevention that may enhance adherence. Prescribers should also consider the wide variety of adjustments that individuals need to make to cope with daily medication.
format Online
Article
Text
id pubmed-4593141
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-45931412015-10-08 Process evaluation of the impact and acceptability of a polypill for prevention of cardiovascular disease Wood, Frances Salam, Abdul Singh, Kavita Day, Sophie Jan, Stephen Prabhakaran, Dorairaj Rodgers, Anthony Patel, Anushka Thom, Simon Ward, Helen BMJ Open Cardiovascular Medicine IMPORTANCE: The Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE) trial has shown improved adherence with the use of a polypill strategy when compared with usual medications for cardiovascular disease (CVD) prevention. To advance from efficacy to impact, we need a better understanding of why and how such a strategy might be deployed in complex health systems. OBJECTIVE: To understand, from the perspective of UMPIRE trial participants and professionals, how and why a polypill strategy improves adherence compared with usual care, why improvement is greater in some subgroups, and to explore the acceptability of a polypill strategy among trial participants and healthcare professionals. DESIGN, SETTING AND PARTICIPANTS: A preplanned process evaluation, based on qualitative interviews, was conducted with a subsample of 102 trial participants and 41 healthcare professionals at the end of the UMPIRE trial in India and Europe. RESULTS: Most patients contrasted the simplicity of the polypill with usual medications that they found complex and, for many in India, expensive. Patients with low baseline adherence struggled most with complex medication lists, and those without established disease described less motivation to adhere when compared with people who had already been diagnosed with CVD; people in the latter group had already undertaken self-directed measures to adhere to CVD preventive medicines prior to entering the trial. Taking medication was one of many adaptations described by patients; these included dietary changes, stopping smoking and maintaining exercise. Most patients liked the polypill strategy, although some participants and health professionals were concerned that it would provide less tailored therapy for individual needs. CONCLUSIONS: Adherence to treatment lists with multiple medications is complex and influenced by several factors. Simplifying medication by using a once-daily polypill is one approach to CVD prevention that may enhance adherence. Prescribers should also consider the wide variety of adjustments that individuals need to make to cope with daily medication. BMJ Publishing Group 2015-09-30 /pmc/articles/PMC4593141/ /pubmed/26423850 http://dx.doi.org/10.1136/bmjopen-2015-008018 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/
spellingShingle Cardiovascular Medicine
Wood, Frances
Salam, Abdul
Singh, Kavita
Day, Sophie
Jan, Stephen
Prabhakaran, Dorairaj
Rodgers, Anthony
Patel, Anushka
Thom, Simon
Ward, Helen
Process evaluation of the impact and acceptability of a polypill for prevention of cardiovascular disease
title Process evaluation of the impact and acceptability of a polypill for prevention of cardiovascular disease
title_full Process evaluation of the impact and acceptability of a polypill for prevention of cardiovascular disease
title_fullStr Process evaluation of the impact and acceptability of a polypill for prevention of cardiovascular disease
title_full_unstemmed Process evaluation of the impact and acceptability of a polypill for prevention of cardiovascular disease
title_short Process evaluation of the impact and acceptability of a polypill for prevention of cardiovascular disease
title_sort process evaluation of the impact and acceptability of a polypill for prevention of cardiovascular disease
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4593141/
https://www.ncbi.nlm.nih.gov/pubmed/26423850
http://dx.doi.org/10.1136/bmjopen-2015-008018
work_keys_str_mv AT woodfrances processevaluationoftheimpactandacceptabilityofapolypillforpreventionofcardiovasculardisease
AT salamabdul processevaluationoftheimpactandacceptabilityofapolypillforpreventionofcardiovasculardisease
AT singhkavita processevaluationoftheimpactandacceptabilityofapolypillforpreventionofcardiovasculardisease
AT daysophie processevaluationoftheimpactandacceptabilityofapolypillforpreventionofcardiovasculardisease
AT janstephen processevaluationoftheimpactandacceptabilityofapolypillforpreventionofcardiovasculardisease
AT prabhakarandorairaj processevaluationoftheimpactandacceptabilityofapolypillforpreventionofcardiovasculardisease
AT rodgersanthony processevaluationoftheimpactandacceptabilityofapolypillforpreventionofcardiovasculardisease
AT patelanushka processevaluationoftheimpactandacceptabilityofapolypillforpreventionofcardiovasculardisease
AT thomsimon processevaluationoftheimpactandacceptabilityofapolypillforpreventionofcardiovasculardisease
AT wardhelen processevaluationoftheimpactandacceptabilityofapolypillforpreventionofcardiovasculardisease